Multi-institutional or international patient registries serve as a research infrastructure for studying rare disease subtypes by pooling observational data across otherwise underpowered single-center or single-country cohorts, enabling better characterization of natural history, prognosis, and comparative treatment effectiveness. In hematologic oncology, this registry-based approach is used when randomized trial data are sparse for rare malignancy subtypes, allowing prospective tracking of treatment regimens and outcomes across cooperating registries. The underlying methodological principle concerns statistical power and generalizability: consolidating fragmented data sources to answer questions about disease course and therapeutic benefit that no single registry can resolve alone.
Multi-institutional or international patient registries serve as a research infrastructure for studying rare disease subtypes by pooling observational data across otherwise underpowered single-center…